Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

Rowe, T., Abernathy, R. A., Hu‐Primmer, J., Thompson, W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 812 · see citing works

Influenza vaccine: The challenge of antigenic drift

Carrat, F., & Flahault, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 704 · see citing works

Textbook of Influenza

(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 663 · see citing works

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333 · see citing works

Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy

Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J., Zambon, M. C. F. A., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 286 · see citing works

Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly

de Jong, J. C., BEYER, W. E. P., Palache, A. M., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200005)61:1 · Cited by 229 · see citing works

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

DONATO, S. D., Granoff, D. M., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 185 · see citing works

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

BEYER, W. E. P., Palache, A. M., Lüchters, G., Nauta, J. J. P., & Osterhaus, A. D. M. E. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.024 · Cited by 179 · see citing works

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 174 · see citing works

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

Gasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 128 · see citing works

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119 · see citing works

Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases

Baldo, V., Baldovin, T., Floreani, A., Fragapane, E., Trivello, R., & The Family Medicine Group (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9100-4 · Cited by 43 · see citing works

Neutralization enzyme immunoassay for influenza virus

Benne, C. A., Harmsen, M., de Jong, J. C., & Kraaijeveld, C. A. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.987-990.1994 · Cited by 37 · see citing works

New A/H3N2 Influenza Variant: a Small Genetic Evolution but a Heavy Burden on the Italian Population during the 2004-2005 Season

Ansaldi, F., Icardi, G., Gasparini, R., Campello, C., Puzelli, S., Bella, A., Donatelli, I., Salmaso, S., & Crovari, P. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.3027-3029.2005 · Cited by 26 · see citing works

An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home

Iorio, A. M., Neri, M., Lepri, E., Camilloni, B., Basileo, M., Sigismondi, N., Fabiani, C., Calzoletti, L., Puzelli, S., & Donatelli, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.037 · Cited by 21 · see citing works

Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine

Kojimahara, N., Maeda, A., KASE, T., & Yamaguchi, N. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.009 · Cited by 19 · see citing works

Neutralizing and Hemagglutination-Inhibiting Activities of Antibodies Elicited by the 2004-2005 Influenza Vaccine against Drifted Viruses

Ansaldi, F., Bacilieri, S., Banfi, F., Durando, P., Sticchi, L., Icardi, G., & Gasparini, R. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.1.162-164.2006 · Cited by 13 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

Advances in aluminum hydroxide-based adjuvant research and its mechanism

Peng, H., Zou, Y., & Hu, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004026 · Cited by 415 · see citing works

Traditional and New Influenza Vaccines

Wong, S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372 · see citing works

The history of MF59 ® adjuvant: a phoenix that arose from the ashes

O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 318 · see citing works

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

Calabrό, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., Gregorio, E. D., O’Hagan, D. T., Baudner, B. C., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 215 · see citing works

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

Banzhoff, A., Gasparini, R., Pasini, F. L., Staniscia, T., Durando, P., Montomoli, E., Capecchi, P., Giovanni, P. D., Sticchi, L., Gentile, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004384 · Cited by 194 · see citing works

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O’Hagan, D. T., & Podda, A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 191 · see citing works

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

Pellegrini, M., Nicolay, U., LINDERT, K. A., Groth, N., & Cioppa, G. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.101 · Cited by 183 · see citing works

Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly

Pereira, B. I., Xu, X., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 182 · see citing works

Vaccines for the elderly: current use and future challenges

Weinberger, B. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0107-2 · Cited by 164 · see citing works

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Wilkins, A. L., Kazmin, D. A., Napolitani, G., Clutterbuck, E., Pulendran, B., Siegrist, C., & Pollard, A. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01760 · Cited by 159 · see citing works

MF59 adjuvant: the best insurance against influenza strain diversity

O’Hagan, D. T., Rappuoli, R., Gregorio, E. D., Tsai, T. F., & Giudice, G. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.23 · Cited by 150 · see citing works

Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses

Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110632 · Cited by 143 · see citing works

Inactivated influenza vaccines

Fiore, A. E., Bridges, C. B., Katz, J. M., & Cox, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00026-4 · Cited by 135 · see citing works

Influenza control in the 21st century: Optimizing protection of older adults

Monto, A. S., Ansaldi, F., Aspinall, R., McElhaney, J. E., Montaño, L. F., Nichol, K. L., Puig‐Barberà, J., Schmitt, J., & Stephenson, I. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.032 · Cited by 125 · see citing works

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults

Tsai, T. F. (2013) · Infection & Chemotherapy · doi:10.3947/ic.2013.45.2.159 · Cited by 107 · see citing works

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

Ansaldi, F., Zancolli, M., Durando, P., Montomoli, E., Sticchi, L., Del Giudice, G., & Icardi, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.030 · Cited by 96 · see citing works

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: Safety and immunogenicity

Salemi, S., Diamanti, A. P., Germano, V., Donatelli, I., Martino, A. D., Facchini, M., Nisini, R., Biselli, R., Ferlito, C., Podestà, E., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.014 · Cited by 94 · see citing works

Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection

Wang, B., Xu, R., Quan, F., Kang, S., Wang, L., & Compans, R. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013972 · Cited by 89 · see citing works

Emulsion-based adjuvants for influenza vaccines

Vogel, F. R., Caillet, C., Kusters, I. C., & Haensler, J. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.5 · Cited by 85 · see citing works

Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial

Hung, I. F., Zhang, J., To, K. K., Chan, J. F., Li, P., Wong, T.-L., Zhang, R., Chan, T.-C., Chan, B. C.-Y., Wai, H. H., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00354-0 · Cited by 84 · see citing works

Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis

Ng, T. W. Y., Cowling, B. J., Gao, H., & Thompson, M. G. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy720 · Cited by 75 · see citing works

Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine

Durando, P., Iudici, R., Alicino, C., Alberti, M., de Florentiis, D., Ansaldi, F., & Icardi, G. (2011) · Human Vaccines · doi:10.4161/hv.7.0.14560 · Cited by 74 · see citing works

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

Keitel, W. A., Groth, N., Lattanzi, M., Praus, M., Hilbert, A. K., Borkowski, A., & Tsai, T. F. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.019 · Cited by 73 · see citing works

Inactivated and Adjuvanted Influenza Vaccines

Giudice, G. D., & Rappuoli, R. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_406 · Cited by 72 · see citing works

MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

Banzhoff, A., Pellegrini, M., Giudice, G. D., Fragapane, E., Groth, N., & Podda, A. (2008) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2008.00059.x · Cited by 70 · see citing works

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

Durando, P., Icardi, G., & Ansaldi, F. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003724662 · Cited by 65 · see citing works

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Camilloni, B., Basileo, M., Valente, S., Nunzi, E., & Iorio, A. M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011562 · Cited by 60 · see citing works

Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Icardi, G., Orsi, A., Ceravolo, A., & Ansaldi, F. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18419 · Cited by 59 · see citing works

Intanza®: a new intradermal vaccine for seasonal influenza

Atmar, R. L., Patel, S. M., & Keitel, W. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.134 · Cited by 59 · see citing works

Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

Baldo, V., Baldovin, T., Pellegrini, M., Angiolelli, G., Majori, S., Floreani, A., Busana, M. C., Bertoncello, C., & Trivello, R. (2010) · Journal of Immunology Research · doi:10.1155/2010/517198 · Cited by 55 · see citing works

Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

Vesikari, T., Forstén, A., Herbinger, K., Cioppa, G. D., Beygo, J., Borkowski, A., Groth, N., Bennati, M., & von Sonnenburg, F. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.009 · Cited by 55 · see citing works

Aging and Options to Halt Declining Immunity to Virus Infections

Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681449 · Cited by 55 · see citing works

Inactivated Influenza Vaccines

Parodi, V., de Florentiis, D., Martini, M., & Ansaldi, F. (2011) · Drugs & Aging · doi:10.2165/11586770-000000000-00000 · Cited by 53 · see citing works

New technologies for influenza vaccines

Dormitzer, P. R., Tsai, T. F., & Giudice, G. D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18859 · Cited by 54 · see citing works

Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN

Mallick, A. I., Parvizi, P., Read, L. R., Nagy, É., Behboudi, S., & Sharif, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.046 · Cited by 53 · see citing works

Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis

Dell’Era, L., Corona, F., Daleno, C., Scala, A., Principi, N., & Esposito, S. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.083 · Cited by 52 · see citing works

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons

Boikos, C., Fischer, L., O’Brien, D., Vasey, J., Sylvester, G. C., & Mansi, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab152 · Cited by 51 · see citing works

Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

Esposito, S., Marchisio, P., Prada, E., Daleno, C., Porretti, L., Carsetti, R., Bosco, A., Ierardi, V., Scala, A., & Principi, N. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.055 · Cited by 50 · see citing works

Efficacy of Vaccination with Different Combinations of MF59-Adjuvanted and Nonadjuvanted Seasonal and Pandemic Influenza Vaccines against Pandemic H1N1 (2009) Influenza Virus Infection in Ferrets

van den Brand, J. M. A., Kreijtz, J. H. C. M., Bodewes, R., Stittelaar, K. J., van Amerongen, G., Kuiken, T., Simon, J. H., Fouchier, R. A. M., Giudice, G. D., Rappuoli, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.01939-10 · Cited by 49 · see citing works

Pneumonia immunization in older adults: review of vaccine effectiveness and strategies

El-Solh, A., Assaad, El-Masri, & Porhomayon, J. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s29675 · Cited by 48 · see citing works

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control

Kreijtz, J. H. C. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2009) · Human Vaccines · doi:10.4161/hv.5.3.6986 · Cited by 46 · see citing works

Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1 H -benzimidazol-2-amines

Beesu, M., Malladi, S. S., Fox, L. M., Jones, C. D., Dixit, A., & David, S. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500701q · Cited by 43 · see citing works

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)

Cheng, A. C., Holmes, M., Dwyer, D. E., Senenayake, S., Cooley, L., Irving, L. B., Simpson, G., Korman, T. M., Macartney, K. K., Friedman, N. D., et al. (2019) · Communicable Diseases Intelligence · doi:10.33321/cdi.2019.43.39 · Cited by 42 · see citing works

Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization

Thomas-Crusells, J., McElhaney, J. E., & Aguado, M. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.025 · Cited by 39 · see citing works

Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

Ansaldi, F., Durando, P., & Icardi, G. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557658 · Cited by 41 · see citing works

Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond

Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 43 · see citing works

Cross-protection against drifted influenza viruses

Orsi, A., Ansaldi, F., de Florentiis, D., Ceravolo, A., Parodi, V., Canepa, P., Coppelli, M., Icardi, G., & Durando, P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23239 · Cited by 39 · see citing works

Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia

Ventura, R., Brunner, L., Heriyanto, B., de Boer, O., O’Hara, M., Huynh, C., Suhardono, M., & Collin, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.074 · Cited by 39 · see citing works

Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity

Li, Z., Zhao, Y., Li, Y., & Chen, X. (2021) · Vaccines · doi:10.3390/vaccines9020075 · Cited by 40 · see citing works

Advances in Adjuvanted Influenza Vaccines

Shichinohe, S., & Watanabe, T. (2023) · Vaccines · doi:10.3390/vaccines11081391 · Cited by 37 · see citing works

Vaccinology in the third millennium: scientific and social challenges

Poland, G. A., Whitaker, J. A., Poland, C. M., Ovsyannikova, I. G., & Kennedy, R. B. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.003 · Cited by 36 · see citing works

MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines

Tsai, T. F. (2011) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.131.1733 · Cited by 36 · see citing works

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)

Cheng, A. C., Holmes, M., Dwyer, D. E., Senenayake, S., Cooley, L., Irving, L. B., Simpson, G., Korman, T. M., Macartney, K. K., Friedman, N. D., et al. (2019) · Communicable Diseases Intelligence · doi:10.33321/cdi.2019.43.48 · Cited by 34 · see citing works

Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canada

Fisman, D. N., & Tuite, A. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027420 · Cited by 33 · see citing works

Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children

Esposito, S., Giavoli, C., Trombetta, C. M., Bianchini, S., Montinaro, V., Spada, A., Montomoli, E., & Principi, N. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.019 · Cited by 33 · see citing works

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses

Fox, A., Carolan, L. A., Leung, V. K. Y., Phuong, H. V. M., Khvorov, A., Auladell, M. A., Tseng, Y., Thái, P. Q., Barr, I., Subbarao, K., et al. (2022) · Viruses · doi:10.3390/v14030470 · Cited by 32 · see citing works

Available influenza vaccines: immunization strategies, history and new tools for fighting the disease.

Barberis, I., Martini, M., Iavarone, F., & Orsi, A. (2016) · PubMed Central · Cited by 30 · see citing works

Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection

Haupt, R. E., Harberts, E. M., Kitz, R. J., Strohmeier, S., Krammer, F., Ernst, R. K., & Frieman, M. B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.085 · Cited by 27 · see citing works

Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants

Hernandez‐Davies, J. E., Dollinger, E., Pone, E. J., Felgner, J. H., Liang, L., Strohmeier, S., Jan, S., Albin, T. J., Jain, A., Nakajima, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12727-y · Cited by 27 · see citing works

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection

Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., Icardi, G., & Durando, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.081 · Cited by 27 · see citing works

Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

Hernandez‐Davies, J. E., Felgner, J. H., Strohmeier, S., Pone, E. J., Jain, A., Jan, S., Nakajima, R., Jasinskas, A., Strahsburger, E., Krammer, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692151 · Cited by 26 · see citing works

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice

Wang, J., Hilchey, S. P., DeDiego, M. L., Perry, S., Hyrien, O., Nogales, A., Garigen, J., Amanat, F., Huertas, N., Krammer, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193680 · Cited by 25 · see citing works

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

Hatz, C., von Sonnenburg, F., Casula, D., Lattanzi, M., & Leroux-Roels, G. G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.017 · Cited by 25 · see citing works

Inactivated Influenza Vaccines

Bresee, J., Fry, A. M., Sambhara, S. R., & Cox, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00031-6 · Cited by 24 · see citing works

Influenza Vaccines: Unmet Needs and Recent Developments

Noh, J. Y., & Kim, W. J. (2013) · Infection and Chemotherapy · doi:10.3947/ic.2013.45.4.375 · Cited by 24 · see citing works

Adjuvants in tuberculosis vaccine development

Moreno-Mendieta, S. A., Rocha‐Zavaleta, L., & Rodrı́guez-Sanoja, R. (2009) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2009.00629.x · Cited by 23 · see citing works

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season

Imran, M., Puig‐Barberà, J., Ortiz, J. R., Fischer, L., O’Brien, D., Bonafede, M., Mansi, J. A., & Boikos, C. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac167 · Cited by 22 · see citing works

A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months

Esposito, S., Marchisio, P., Ansaldi, F., Bianchini, S., Pacei, M., Baggi, E., Trabattoni, D., Icardi, G., & Principi, N. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.041 · Cited by 22 · see citing works

Immunogenicity and safety of intradermal influenza vaccine in children

Esposito, S., Daleno, C., Picciolli, I., Tagliaferri, L., Scala, A., Prunotto, G., Montinaro, V., Galeone, C., & Principi, N. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.021 · Cited by 22 · see citing works

Biodistribution and mechanisms of action of MF59 and MF59-like adjuvants

Zhang, W., Cui, H., Xu, J., Shi, M., Bian, L., Cui, L., Jiang, C., & Zhang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.044 · Cited by 21 · see citing works

Emulsion-Based Adjuvants for Improved Influenza Vaccines

O’Hagan, D. T., Tsai, T. F., & Reed, S. G. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2_14 · Cited by 21 · see citing works

Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications

Boikos, C., Imran, M., Nguyen, V. H., Ducruet, T., Sylvester, G. C., & Mansi, J. A. (2021) · Vaccines · doi:10.3390/vaccines9080862 · Cited by 20 · see citing works

Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine

Short, K. K., Lathrop, S. K., Davison, C. J., Partlow, H. A., Kaiser, J. A., Tee, R. D., Lorentz, E. B., Evans, J. T., & Burkhart, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071455 · Cited by 20 · see citing works

Establishment of a novel safety assessment method for vaccine adjuvant development

Sasaki, E., Momose, H., Hiradate, Y., Mizukami, T., & Hamaguchi, I. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.009 · Cited by 18 · see citing works

Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.

Iannazzo, S. (2011) · PubMed · Cited by 18 · see citing works

Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults

Domnich, A., Panatto, D., Pariani, E., Napoli, C., Chironna, M., Manini, I., Rizzo, C., Orsi, A., & Icardi, G. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.041 · Cited by 17 · see citing works

Influenza virus surveillance in migratory ducks and sentinel ducks at Poyang Lake, China.

Duan, L., Zhu, H., Wang, J., Huang, K., Cheung, C.-L., Peiris, J. S. M., Chen, H., & Guan, Y. (2011) · PubMed · Cited by 17 · see citing works

Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine

Fox, A., Quinn, K. M., & Subbarao, K. (2018) · Drugs · doi:10.1007/s40265-018-0958-7 · Cited by 17 · see citing works

Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity

Wheatley, A. K., & Kent, S. J. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1068125 · Cited by 17 · see citing works

Opportunities and challenges in vaccine delivery

Carstens, M. G. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.004 · Cited by 17 · see citing works

Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)

Pott, H., Andrew, M. K., Shaffelburg, Z., Nichols, M. K., Ye, L., ElSherif, M. S., Hatchette, T. F., LeBlanc, J. J., Ambrose, A., Boivin, G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.070 · Cited by 16 · see citing works

Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses

Mohan, T., Kim, J., Berman, Z., Wang, S., Compans, R. W., & Wang, B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.021 · Cited by 16 · see citing works

MF59

Kommareddy, S., Singh, M., & O’Hagan, D. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00013-x · Cited by 16 · see citing works

Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials

Youhanna, J. E., Tran, V., Hyer, R. N., & Domnich, A. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13286 · Cited by 16 · see citing works

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis

Domnich, A., Trombetta, C.-S., Fallani, E., & Salvatore, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310677 · Cited by 14 · see citing works

Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives

Ilyinskii, P. O., Thoidis, G., & Shneider, A. M. (2008) · International Reviews of Immunology · doi:10.1080/08830180802295765 · Cited by 14 · see citing works

Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season

Imran, M., Puig‐Barberà, J., Ortiz, J. R., López-González, L., Dean, A., Bonafede, M., & Haag, M. D. M. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13288 · Cited by 15 · see citing works

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™

Xu, S., Duan, H., An, Y., Jin, X., Duan, M., Dubois, P. M., Huang, Y., Xu, K., Du, H., Kleanthous, H., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.035 · Cited by 12 · see citing works

Protection Against Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Enteritidis Infection in Layer Chickens Conferred by a Live Attenuated Salmonella Typhimurium Strain

Lee, J. H. (2015) · Immune Network · doi:10.4110/in.2015.15.1.27 · Cited by 13 · see citing works

MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications

Patel, S. S., Bizjajeva, S., Heijnen, E., & Oberyé, J. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.04.023 · Cited by 13 · see citing works

Inactivated Influenza Vaccines:

Lang, P. O. (2011) · Drugs & Aging · doi:10.2165/11592350-000000000-00000 · Cited by 12 · see citing works

Vaccines and Senior Travellers

Ecarnot, F., Maggi, S., Michel, J., Veronese, N., & Rossanese, A. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.677907 · Cited by 12 · see citing works

Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects

Chanthavanich, P., Versage, E. M., van Twuijver, E., & Hohenboken, M. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.010 · Cited by 13 · see citing works

Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus

Esposito, S., Daleno, C., Tagliabue, C., Scala, A., Picciolli, I., Taroni, F., Galeone, C., Baldanti, F., & Principi, N. (2011) · Virology Journal · doi:10.1186/1743-422x-8-563 · Cited by 10 · see citing works

Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons

Lapi, F., Domnich, A., Marconi, E., Rossi, A., & Cricelli, C. A. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2115362 · Cited by 10 · see citing works

Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults

Frey, S. S., Versage, E. M., van Twuijver, E., & Hohenboken, M. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2193119 · Cited by 10 · see citing works

Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults

Vanderven, H. A., Barr, I., Reynaldi, A., Wheatley, A. K., Wines, B. D., Davenport, M. P., Hogarth, P. M., & Kent, S. J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.066 · Cited by 10 · see citing works

Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine

Palladino, G., Ferrari, A., Music, N., Settembre, E. C., & Wen, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.021 · Cited by 9 · see citing works

Surveillance of Severe Acute Respiratory Infection and Influenza Vaccine Effectiveness among Hospitalized Italian Adults, 2021/22 Season

Panatto, D., Domnich, A., Chironna, M., Loconsole, D., Napoli, C., Torsello, A., Manini, I., Montomoli, E., Pariani, E., Castaldi, S., et al. (2022) · Vaccines · doi:10.3390/vaccines11010083 · Cited by 9 · see citing works

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection

Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., Icardi, G., & Durando, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.081 · Cited by 27 · see citing works

Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine

Palladino, G., Ferrari, A., Music, N., Settembre, E. C., & Wen, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.021 · Cited by 9 · see citing works

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

Durando, P., Icardi, G., & Ansaldi, F. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003724662 · Cited by 65 · see citing works

Research Article Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

Baldo, V., Baldovin, T., Pellegrini, M., Angiolelli, G., Majori, S., Floreani, A., Busana, M. C., Bertoncello, C., & Trivello, R. (2010)

Cross-protection against drifted influenza viruses

Orsi, A., Ansaldi, F., de Florentiis, D., Ceravolo, A., Parodi, V., Canepa, P., Coppelli, M., Icardi, G., & Durando, P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23239 · Cited by 39 · see citing works